BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 9080118)

  • 1. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
    Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
    Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
    Provinciali M; Argentati K; Tibaldi A
    Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines.
    Clary BM; Coveney EC; Blazer DG; Philip R; Lyerly HK
    Surgery; 1996 Aug; 120(2):174-81. PubMed ID: 8751580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
    Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
    Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
    Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
    Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer.
    Kim HS; Choo YS; Koo T; Bang S; Oh TY; Wen J; Song SY
    Immunol Lett; 2006 Mar; 103(2):142-8. PubMed ID: 16313973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
    Berman RM; Suzuki T; Tahara H; Robbins PD; Narula SK; Lotze MT
    J Immunol; 1996 Jul; 157(1):231-8. PubMed ID: 8683120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
    Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
    Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
    Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
    Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.
    Vieweg J; Rosenthal FM; Bannerji R; Heston WD; Fair WR; Gansbacher B; Gilboa E
    Cancer Res; 1994 Apr; 54(7):1760-5. PubMed ID: 8137291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
    Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
    Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
    Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
    Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.
    Lichtor T; Glick RP; Tarlock K; Moffett S; Mouw E; Cohen EP
    Cancer Gene Ther; 2002 May; 9(5):464-9. PubMed ID: 11961669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
    Tahara H; Zeh HJ; Storkus WJ; Pappo I; Watkins SC; Gubler U; Wolf SF; Robbins PD; Lotze MT
    Cancer Res; 1994 Jan; 54(1):182-9. PubMed ID: 7903204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
    Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis.
    Mazzolini G; Narvaiza I; Martinez-Cruz LA; Arina A; Barajas M; Galofré JC; Qian C; Mato JM; Prieto J; Melero I
    Gene Ther; 2003 Jul; 10(13):1067-78. PubMed ID: 12808437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.